Drug testing in mouse models of tuberculosis and nontuberculous mycobacterial infections

Tuberculosis

Volumn 93, Issue 3, 2013, Pages 285-290

  Nikonenko, Boris V ^a   Apt, Alexander S ^b  

^a SEQUELLA INC   (United States)

^b CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

Author keywords

Drug treatment; Inbred mouse strains; Mycobacterium tuberculosis; Non tuberculosis mycobacterium

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE;

ATYPICAL MYCOBACTERIOSIS; CROHN DISEASE; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SCREENING; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM PARATUBERCULOSIS; PARATUBERCULOSIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; MICE; MICE, INBRED STRAINS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; TUBERCULOSIS;

EID: 84875808742     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2013.02.010     Document Type: Review

References (95)

1. J.L. Flynn Lessons from experimental Mycobacterium tuberculosis infections Microbe Infec 8 2006 1179 1188
2. D.N. McMurray, F.M. Collins, A.M. Dannenberg Jr., and D.W. Smith Pathogenesis of experimental tuberculosis in animal models Curr Top Microbiol Immunol 215 1996 157 179
3. E.R. Rhoades, A.A. Frank, and I.M. Orme Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis Tuber Lung Dis 78 1997 57 66
4. M.C. Tsai, S. Chakravarty, G. Zhu, J. Xu, K. Tanaka, C. Koch, J. Tufariello, J. Flynn, and J. Chan Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension Cell Microbiol 8 2006 218 232
5. A.S. Apt Are mouse models of human mycobacterial diseases relevant? genetics says: "yes!" Immunology 134 2011 109 115
6. A. Apt, and I. Kramnik Man and mouse TB: contradictions and solutions Tuberculosis (Edinb) 89 2009 195 198
7. D. Young Animal models of tuberculosis Eur J Immunol 39 2009 2011 2014
8. E. Bogatcheva, C. Hanrahan, B. Nikonenko, R. Samala, P. Chen, J. Gearhart, F. Barbosa, L. Einck, C.A. Nacy, and M. Protopopova Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis J Med Chem 49 2006 3045 3048
9. A.J. Lenaerts, V. Gruppo, J.V. Brooks, and I.M. Orme Rapid in vivo screening of experimental drugs for tuberculosis using γ- interferon gene-disrupted mice Antimicrob Agents Chemother 47 2003 783 785
10. A.J. Lenaerts, V. Gruppo, K.S. Marietta, C.M. Johnson, D.K. Driscoll, N.M. Tompkins, J.D. Rose, R.C. Reynolds, and I.M. Orme Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models Antimicrob Agents Chemother 49 2005 2294 2301
11. M. Matsumoto, H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsubouchi, H. Sasaki, Y. Shimokawa, and M. Komatsu OPC-67683, a nitro-dihydro-imidazooxazole derivate with promising action against tuberculosis in vitro in mice Plos Med 3 2006 2131 2143
12. B.V. Nikonenko, R. Samala, L. Einck, and C.A. Nacy Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis Antimicrob Agents Chemother 48 2004 4550 4555
13. J. Grosset, and B. Ji Experimental chemotherapy of mycobacterial diseases P.R.J. Gangadharam, P.A. Jenkins, Mycobacteria Chemotherapy vol. II 1998 Chapman & Hall New York 51 97
14. S. Tyagi, E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis Antimicrob Agents Chemother 49 2005 2289 2293
15. E.J. Alvirez-Freites, J.L. Carter, and M.H. Cynamon In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis Antimicrob Agents Chemother 46 2002 1022 1025
16. K. Andries, P. Verhasselt, J. Guillemont, H.W. Göhlmann, J.M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227
17. M.H. Cynamon, and M. Sklaney Gatifloxacin and ethionamide as foundation for therapy of tuberculosis Antimicrob Agents Chemother 47 2003 2442 2444
18. N. Daniel, N. Lounis, B. Ji, R.J. O'Brien, A. Vernon, L.J. Geiter, M. Szpytma, C. Truffot-Pernot, G. Hejblum, and J. Grosset Anti tuberculosis activity of once weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimen Am J Respir Crit Care Med 161 2000 1572 1577
19. J. Grosset, C. Truffot-Pernot, C. Lacroix, and B. Ji Antagonism between isoniazid and the combination pirazinamide-rifampin against tuberculosis infection in mice Antimicrob Agents Chemother 36 1992 548 551
20. L. Jia, J.E. Tomaszewski, C. Hanrahan, L. Coward, P. Noker, G. Gorman, B. Nikonenko, and M. Protopopova Pharmacodynamics and pharmacokinetics of SQ109 a new diamine-based antitubercular drug Brit J Pharmacol 144 2005 80 87
21. A.M. Lenaerts, S.E. Chase, A.J. Chmielewski, and M.H. Cynamon Evaluation of rifapentine in long-term treatment regimen for tuberculosis in mice Antimicrob Agents Chemother 43 1999 2356 2360
22. N. Lounis, N. Veziris, A. Chauffour, C. Truffot-Pernot, K. Andries, and V. Jarlier Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration Antimicrob Agents Chemother 50 2006 3543 3547
23. B.V. Nikonenko, L. Einck, and C. Nacy Anti-tuberculosis drug therapy in mice of different inbred strains Infect Genet Evolut 10 2010 1151 1154
24. B.V. Nikonenko, M. Protopopova, R. Samala, L. Einck, and C.A. Nacy Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs Antimicrob Agents Chemother 51 2007 1563 1565
25. B.V. Nikonenko, V.M. Reddy, M. Protopopova, E. Bogatcheva, L. Einck, and C.A. Nacy Capuramycin analog in a murine model of tuberculosis Antimicrob Agents Chemother 53 2009 3138 3139
26. B.V. Nikonenko, K.A. Sacksteder, S. Hundred, L. Einck, and C.A. Nacy Preclinical study of new TB drugs and drug combinations in mouse models Resent Pat Anti-infect Drug Disc 3 2008 102 116
27. M. Protopopova, C. Hanrahan, B. Nikonenko, R. Samala, P. Chen, J. Gearhart, L. Einck, and C.A. Nacy Indemnification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamins J Antimicrob Chemother 56 2005 968 974
28. N. Veziris, M. Ibrahim, N. Lounis, K. Andries, and V. Jarlier Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis PLoS One 6 3 2011 e17556
29. J.V. Brooks, and I.M. Orme Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins n the mouse aerosol infection model Antimicrob Agents Chemother 42 1998 3047 3048
30. R. Jayaram, S. Gaonkar, P. Kaur, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R.K. Shandil, E. Kantharaj, and V. Balasubramanian Pharmacokinetics-pharmacodinamics of rifampin in aerosol infection model of tuberculosis Antimicrob Agents Chemother 47 2003 2118 2124
31. R. Jayaram, R.K. Shandil, S. Gaonkar, P. Kaur, B.L. Suresh, B.N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, E. Kantharaj, and V. Balasubramanian Isoniazid pharmacokinetics-parmacodinamics in aerosol infection model of tuberculosis Antimicrob Agents Chemother 48 2004 2951 2957
32. B.P. Kelly, S.K. Furney, M.T. Jessen, and I.M. Orme Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis Antimicrob Agents Chemother 40 1996 2809 2812
33. E. Nuermberger, I. Rosenthal, S. Tyagi, K.N. Williams, D. Almeida, C.A. Peloquin, W.R. Bishai, and J.H. Grosset Combination chemotherapy with nitroimidazopyran PA-824 in a murine model of tuberculosis Antimicrob Agents Chemother 50 2006 2621 2625
34. E. Nuermberger, S. Tyagi, K. Williams, I. Rosenthal, W. Bishai, and J.H. Grosset Rifapentine, moxifloxacin or DNA vaccine improves treatment of latent tuberculosis in a mouse model Am J Respir Crit Care Med 172 2005 1452 1456
35. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, R.J. O'Brien, A.N. Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset Moxifloxacin containing regimen greatly reduces time to culture conversation in murine tuberculosis Am J Respir Crit Care Med 169 2004 421 426
36. I. Orme Cellular and genetic mechanisms underlying susceptibility of animal models to tuberculosis infection Novartis Found Symp 217 1998 112 117 [discussion 117-9]
37. I. Orme, J. Secrist, S. Anathan, C. Kwong, J. Maddry, R. Reynolds, A. Poffenberger, M. Michael, L. Miller, J. Krahenbuh, L. Adams, A. Biswas, S. Franzblau, D. Rouse, D. Winfield, and J. Brooks Guest commentary. Search for new drugs for treatment of tuberculosis Antimicrob Agents Chemother 45 2001 1943 1946
38. M. Ibrahim, K. Andries, N. Lounis, A. Chauffour, C. Truffot-Pernot, V. Jarlier, and N. Verizis Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis Antimicrob Agents Chemother 51 2007 1011 1015
39. T. Yoshimatsu, E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis Antimicrob Agents Chemother 46 2002 1875 1879
40. K. Andries, T. Gevers, and N. Lounis Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis Antimicrob Agents Chemother 54 2010 4540 4544
41. T.V. Radaeva, B.V. Nikonenko, V.V. Mischenko, M.M. Averbakh Jr., and A.S. Apt Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice Tuberculosis (Edinb.) 85 2005 65 72
42. M. Ibrahim, C. Truffot-Pernot, K. Andries, V. Jarlier, and N. Veziris Sterilizing activity of R20710 (TMC207)-containing regimens in the murine model of tuberculosis Am J Respir Crit Care Med 180 2009 553 557
43. A. Fortin, L. Abel, J.L. Casanova, and P. Gros Host genetics of mycobacterial diseases in mice and men: forward genetic studies of BCG-osis and tuberculosis Annu Rev Genomics Hum Genet 8 2007 163 192
44. E. Schurr, and I. Kramnik Genetic control of host susceptibility to tuberculosis S.H.E. Kaufmann, W.J. Britton, Handbook of tuberculosis: immunology and cell biology 2008 WILEY-VCH Verlag Weinheim 295 336
45. S. Bonora, and G. GDi Perri Interactions between antiretroviral agents and those used to treat tuberculosis Curr Opin HIV AIDS 3 2008 306 312
46. A. Kwara, M. Lartey, K.W. Sagoe, and M.H. Court Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy AIDS 25 2011 388 390
47. R. Zhu, J.J. Kiser, H.I. Seifart, C.J. Werely, C.D. Mitchell, D.Z. D'Argenio, and C.V. Fletcher The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid J Clin Pharmacol 52 2012 511 519
48. R.M. Warren, E.M. Streicher, N.C. Gey van Pittius, B.J. Marais, G.D. van der Spuy, T.C. Victor, F. Sirgel, P.R. Donald, and P.D. Helden The clinical relevance of mycobacterial pharmacogenetics Tuberculosis (Edinb) 89 2009 199 202
49. D.P. Roy, M. Majumder, and B. Roy Pharmacogenomics of anti-TB drugs-related hepatotoxicity Pharmacogenomics 9 2008 311 321
50. M. Zhang, S.-Y. Li, I. Rosental, D.V. Almedia, Z. Ahmad, P.J. Converse, A.P. Charles, E.L. Nuermberger, and J.H. Grosset Treatment of tuberculosis with rifamicin-containing regimens in immune-deficient mice Am J Respir Crit Care Med 183 2011 1254 1261
51. J. Harper, C. Skerry, S.L. Davis, R. Tasneen, M. Weir, I. Kramnik, W.R. Bishai, M.G. Pomper, E.L. Nuermberger, and S.K. Jain Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions J Inf Dis 205 2012 595 602
52. E.R. Driver, G.J. Ryan, D.R. Hoff, S.M. Irwin, R.J. Basaraba, I. Kramnik, and A.J. Lenaerts Evaluation of mouse model forming necrotic granulomas using C3HeB/FeJ mice, for the testing of M. tuberculosis drugs Antimicrob Agents Chemother 56 2012 3181 3195
53. E.V. Kondratieva, N.N. Logunova, K.B. Majorov, M.M. Averbakh, and A.S. Apt Host genetics in granuloma formation: human-like pathology in mice with reciprocal susceptibility to M. tuberculosis and M. avium PLoS One 5 2010 e10515
54. T.V. Radaeva, E.V. Kondratieva, V.V. Sosunov, K.B. Majorov, and A.S. Apt A human-like TB in genetically susceptible mice followed by the true dormancy in a Cornell-like model Tuberculosis (Edinb.) 88 2008 576 585
55. I.M. Orme Development of new vaccines and drugs for TB: limitations and potential strategic errors Future Microbiol 6 2011 161 177
56. N. Veziris, C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo Antimicrob Agents Chemother 47 2003 3117 3122
57. H.F. Lecoeur, P.H. Lagrange, C. Truffot-Pernot, M. Cheorghiu, and J. Grosset Relapse after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice Clin Exp Immunol 76 1989 458 462
58. H.F. Lecoeur, C. Truffot-Pernot, and J.H. Grosset Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide Am Rev Respir Dis 140 1989 1189 1193
59. J. Chan, Y. Tian, K.E. Tanaka, M.S. Tsang, K. Yu, P. Salgame, D. Carroll, Y. Kress, R. Teitelbaum, and B.R. Bloom Effects of protein calorie malnutrition on tuberculosis in:mice PNAS 93 1996 14857 14861
60. L. Levy, and B. Ji The mouse foot-pad technique for cultivation of Mycobacterium leprae Lepr Rev 77 2006 5 24
61. P.J. Converse, V.L. Haines, A. Wondimu, L.E. Craig, and W.M. Meyers Infection of SCID mice with Mycobacterium leprae and control with antigen-activated "immune" human peripheral blood mononuclear cells Infect Immun 63 1995 1047 1054
62. B. Ji, A. Chauffour, K. Andries, and J. Jarlier Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice Antimicrob Agents Chemother 50 2006 1558 1560
63. R.J.W. Rees, and A.G.M. Weddell Experimental model for studying leprosy Ann NY Acad Sci 154 1968 214 236
64. R. Gelber, K. Andries, R.M.D. Paredes, C.E.S. Andrya, and J. Burgos The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered Intermittently Antimicrob Agents Chemother 53 2009 3889 3911
65. J. Burgos, E. De La Cruz, R. Paredes, C.R. Andrya, and R.H. Gelber The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice Lepr Rev 82 2011 253 258
66. C.C. Shepard, and D.H. MacRae A method for counting acid-fast bacteria Int J Lepr 36 1968 78 82
67. L. Heifets Mycobacterial infections caused by nontuberculous mycobacteria Semin Respir Crit Care Med 25 2004 283 295
68. D. Ignatov, E. Kondratieva, T. Azhikina, and A. Apt Mycobacterium avium-triggered diseases: pathogenomics Cell Microbiol 14 2012 808 818
69. M.H. Cynamon, J.L. Carter, and C.M. Shoen Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model Antimicrob Agents Chemother 44 2000 2895 2896
70. P.R.J. Gangadharam Beige mouse model for Mycobacterium avium complex disease Antimicrob Agents Chemother 39 1995 1647 1654
71. B. Ji, N. Lounis, C. Truffot-Pernot, and J. Grosset Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model Antimicrob Agents Chemother 38 1994 2521 2529
72. P. Le Conte, F. Le Gallou, G. Potel, L. Struillou, D. Baron, and H.B. Drugeon Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model Antimicrob Agents Chemother 38 1994 2695 2701
73. E. Ehlers, J. Benini, H.D. Held, C. Roeck, G. Alber, and S. Uhlig αβ T cell receptor-positive cells and interferon-γ, but not inducible nitric oxide synthase, are critical for granuloma necrosis in a mouse model of Mycobacteria-induced pulmonary immunopathology J Exp Med 194 2001 1847 1859
74. E.V. Kondratieva, V.V. Evstifeev, T.K. Kondratieva, S.N. Petrovskaya, A.V. Pichugin, E.I. Rubakova, M.M. Averbakh Jr., and A.S. Apt I/St mice hypersusceptible to Mycobacterium tuberculosis are resistant to M. avium Infect Immun 75 2007 4762 4768
75. S. Roque, C. Nobrega, R. Appelberg, and M. Correia-Neves IL-10 underlies distinct susceptibility of BALB/c and C57BL/6 mice to Mycobacterium avium infection and influences efficacy of antibiotic therapy J Immunol 178 2007 8028 8035
76. M.H. Cynamon, and S.P. Klemens Activity of azithromycin against Mycobacterium avium infection in beige mice Antimicrob Agents Chemother 36 1992 1611 1613
77. S.P. Klemens, and M.H. Cynamon Activity of rifapentine against Mycobacterium avium infection in beige mice J Antimicrob Chemother 29 1992 555 561
78. B. Ji, N. Lounis, C. Truffot-Pernot, and J. Grosset How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex Infections in beige mice? Antimicrob Agents Chemother 40 1996 437 442
79. N.B. Harris, and R.G. Barletta Mycobacterium avium subsp. paratuberculosis in veterinary medicine Clin Microbiol Rev 14 2001 489 512
80. M. Feller, K. Huwiler, R. Stephan, E. Altpeter, A. Shang, H. Furrer, G.E. Pfyffer, T. Jemmi, A. Baumgartner, and M. Egger Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis Lancet Infect Dis 7 2007 607 613
81. L. Golan, A. Livneh-Kol, E. Gonen, S. Yagel, I. Rosenshine, and N.Y. Shpigel Mycobacterium avium paratuberculosis invades human small-intestinal goblet cells and elicits inflammation J Infect Dis 199 2009 350 354
82. J.D. Lalande, and M.A. Behr Mycobacteria in Crohn's disease: how innate immune deficiency may result in chronic inflammation Expert Rev Clin Immunol 6 2010 633 641
83. J.F. Huntley, J.R. Stabel, M.L. Paustian, T.A. Reinhardt, and J.P. Bannantine Expression library immunization confers protection against Mycobacterium avium subsp. paratuberculosis infection Infect Immun 73 2005 6877 6884
84. V. Rosseels, V. Roupie, D. Zinniel, R.G. Barletta, and K. Huygen Development of luminescent Mycobacterium avium subsp. paratuberculosis for rapid screening of vaccine candidates in mice Infect Immun 74 2006 3684 3686
85. T.J. Borody, S. Bilkey, A.R. Wettstein, S. Leis, G. Pang, and S. Tye Antimycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars Dig Liver Dis 39 2007 438 444
86. T.J. Borody, S. Leis, E.F. Warren, and R. Surace Treatment of severe Crohn's disease using antimycobacterial triple therapy-approaching a cure? Dig Liver Dis 34 2002 29 38
87. M. Feller, A. Schoepfer, A. Shang, H. Furrer, and M. Egger Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials Clin Infect Dis 50 2010 473 480
88. W. Selby, P. Pavli, B. Crotty, T. Florin, G. Radford-Smith, P. Gibson, B. Mitchell, W. Connell, R. Read, M. Merrett, H. Ee, and D. Hetzel Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease Gastroenterology 132 2007 2313 2319
89. R.J. Chiodini, J.M. Kreeger, and W.R. Thayer Use of rifabutin in treatment of systemic Mycobacterium paratuberculosis infection in mice Antimicrob Agents Chemother 37 1993 1645 1648
90. G.W. Brumbaugh, R.B. Simpson, J.F. Edwards, D.R. Anders, and T.D. Thomson Susceptibility of Mycobacterium avium sbsp paratuberculosis to monensin sodium or tilmicosin phosphate in vitro and resulting infectivity in a murine model Can J Vet Res 68 2004 175 181
91. P.W. Wright, and R.J. Wallace M.D. Rossman, R.R. MacGregor, Syndromes, diagnosis and treatment of rapidly growing mycobacteria 1995 373 389
92. M. Rottman, E. Catherinot, P. Hochedez, J.-F. Emile, J.-L. Casanova, J.-L. Gaillard, and C. Soudais Importance of T cells, gamma-interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice Infect Immun 75 2007 5898 5907
93. D. Ordway, M. Henao-Tamayo, E. Smith, C. Shanley, M. Harton, J. Troudt, X. Bai, R.J. Basaraba, I.M. Orme, and E.D. Chan Animal model of Mycobacterium abscessus lung infection J Leuk Biol 83 2008 1502 1511
94. E.D. Chan, X. Bai, M. Kartalija, I.M. Orme, and D.J. Ordway Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease Am J Respir Cell Mol Biol 43 2010 387 393
95. M.A. De Groote, J.C. Gilliland, C.L. Wells, E.J. Brooks, L.K. Woolhiser, V. Gruppo, C.A. Peloquin, I.M. Orme, and A.J. Lenaerts Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis Antimicrob Agents Chemother 55 2011 1237 1247